Phase 1 Cardiomyopathy Trial, Recruiting (NCT06209359)

Phase 1 Cardiomyopathy Trial, Recruiting NCT06209359 Sponsor: Yale University Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT06209359 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with heart failure
Your doctors are not planning to change your heart failure medications or devices during the study
You have not had an unplanned hospital stay in the last 2 months
Your fluid levels are considered stable and well-controlled by your medical team
Your blood potassium level is 5.0 or below (confirm with trial site)
Your blood sodium level is 130 or above (confirm with trial site)
Your blood count (hemoglobin) is at or above a minimum level showing you are not severely anaemic (confirm with trial site)
You are over 18 years old
Testing shows that your water tablet (diuretic) medication is not working as well as it should, based on a specific urine test done during a screening visit

Who may not be able to join:

Your kidneys are functioning at a very low level (confirm with trial site)
You have taken certain types of water tablets (non-loop diuretics, except for low-dose spironolactone) in the last 7 days
You have a history of sudden severe fluid build-up in the lungs, or a type of heart failure that is very sensitive to fluid changes, such as amyloid heart disease
Your blood count (hemoglobin) is below the minimum required level
You are currently pregnant or breastfeeding
You have cirrhosis or any known liver disease or liver failure
You have had a blood acid-balance problem (acidosis) in the last 30 days
You are taking metformin, acetazolamide, or any other medication that could affect your blood's acid balance (unless metformin can be safely stopped during the study and your blood sugar is well-controlled)
Your blood bicarbonate or blood pH levels are below the required range at your screening visit (confirm with trial site)
You are unable to give written consent or are unable to follow the study schedule and visits
You are taking lithium
You are taking pimozide or thioridazine
You have a known allergy or medical reason that prevents you from taking sulfonamide-based medicines or thiazide diuretics (a type of water tablet)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jeffrey Testani, MD, Yale University

Phone: 2037373571

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06209359

Sponsor: Yale University

Phase: Phase 1

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: 2037373571

More information: https://clinicaltrials.gov/study/NCT06209359

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with heart failure
Your doctors are not planning to change your heart failure medications or devices during the study
You have not had an unplanned hospital stay in the last 2 months
Your fluid levels are considered stable and well-controlled by your medical team
Your blood potassium level is 5.0 or below (confirm with trial site)
Your blood sodium level is 130 or above (confirm with trial site)
Your blood count (hemoglobin) is at or above a minimum level showing you are not severely anaemic (confirm with trial site)
You are over 18 years old
Testing shows that your water tablet (diuretic) medication is not working as well as it should, based on a specific urine test done during a screening visit

Who may not be able to join:

Your kidneys are functioning at a very low level (confirm with trial site)
You have taken certain types of water tablets (non-loop diuretics, except for low-dose spironolactone) in the last 7 days
You have a history of sudden severe fluid build-up in the lungs, or a type of heart failure that is very sensitive to fluid changes, such as amyloid heart disease
Your blood count (hemoglobin) is below the minimum required level
You are currently pregnant or breastfeeding
You have cirrhosis or any known liver disease or liver failure
You have had a blood acid-balance problem (acidosis) in the last 30 days
You are taking metformin, acetazolamide, or any other medication that could affect your blood's acid balance (unless metformin can be safely stopped during the study and your blood sugar is well-controlled)
Your blood bicarbonate or blood pH levels are below the required range at your screening visit (confirm with trial site)
You are unable to give written consent or are unable to follow the study schedule and visits
You are taking lithium
You are taking pimozide or thioridazine
You have a known allergy or medical reason that prevents you from taking sulfonamide-based medicines or thiazide diuretics (a type of water tablet)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Yale University

Registry

ClinicalTrials.gov

Start date

24 July 2024

Est. completion

1 March 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change of distal sodium reabsorption(ADRNa) between NH4Cl vs. placebo study visits; Change of distal sodium reabsorption(ADRNa) between NH4Cl vs. placebo study visits

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov